Medicare aims to level reimbursement playing field in fight between Elekta and Varian
A new reimbursement proposal from the Center for Medicare & Medicaid Services removes would level payments for brain tumor radiosurgery performed with technology from either Swedish Elekta and California-based Varian.
A new proposal from the Centers for Medicare & Medicaid Services would help level at least 1 battlefield between radiosurgery devices makers Elekta  (STO:EKTA B ) and Varian Medical Systems  (NYSE:VAR ).
The reimbursement proposal would offer equal payment to healthcare providers conducting single-treatment radiosurgery for brain tumors, whether the procedure is conducted with Elekta's Gamma Knife or Varian's Linac.
The decision would reverse a 2012 measure, supported by Senate Majority Leader Harry Reid (D-Nev.), which would cut payments for Elekta's technology.